Rajiv Loungani
Psychiatry · Jacksonville, FLNPI 1447516802
Payments from drug & device makers
Across 272 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Bausch Health US, LLC$1K
- AbbVie$790
- Supernus Pharmaceuticals, Inc.$723
- Johnson & Johnson$277
- plus $945 from 10 others
What the payments were for
- Food & beverage$6,09398%
- Education$1262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $1,248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $1,119 |
| Bausch Health US, LLC | 65 | $1,118 |
| AbbVie(2 entities) | 36 | $790 |
| Supernus Pharmaceuticals, Inc. | 30 | $723 |
| Johnson & Johnson | 7 | $277 |
| Axsome Therapeutics, Inc. | 8 | $227 |
| Lundbeck LLC | 10 | $209 |
| Avanir Pharmaceuticals, Inc. | 1 | $113 |
| Alkermes, Inc. | 1 | $103 |
| Sunovion Pharmaceuticals Inc. | 4 | $72 |
| Noven Therapeutics, LLC | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Neos Therapeutics, LP | 2 | $40 |
| Tris Pharma Inc | 2 | $37 |
| Corium, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,219 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $17,029 |
| Lurasidone Hcl | 11 | $1,996 |
| Clonazepam | 52 | $449 |
| Quetiapine Fumarate | 20 | $370 |
| Gabapentin | 12 | $336 |
| Duloxetine Hcl | 12 | $258 |
| Bupropion XlBupropion Hcl | 22 | $203 |
| Eszopiclone | 12 | $190 |
| Propranolol Hcl | 15 | $165 |
| Diazepam | 19 | $140 |
| Ropinirole Hcl | 11 | $109 |
| Mirtazapine | 12 | $64 |
| Escitalopram Oxalate | 14 | $46 |
| Zolpidem Tartrate | 14 | $41 |
| Alprazolam | 17 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $113 | $17,02912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Jacksonville
- John JoyceJacksonville$13.6M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.